

CURRICULUM VITAE

Roberto Mina, MD

Department of Molecular Biotechnology and Health Sciences
Università degli Studi di Torino
Division of Hematology
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
via Genova 3, 10126 Torino
Tel (011) 6335878

Education

2012

Medical degree (with distinction), University of Torino, Italy

2018

Post-graduate degree in Hematology (with distinction), University of Torino, Italy

Professional records

2012-2013

Internship, Division of Hematology, University of Torino, Italy

8/2013-8/2018

Clinical and Research Fellowship, Hematology division, University of Torino

10/2017-6/2018

Visiting scholar at Winship Cancer Institute Department of hematology and medical oncology, Emory University, Atlanta, Georgia (USA)

9/2018-2019

Research fellow, Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy

2019-present

Tenure track researcher at the University of Torino, Department of Molecular Biotechnology and Health Sciences

Clinical activity

Clinical management of onco-hematological in- and out-patients, comprising bone marrow transplantation. Specifically focused on plasma-cell disorders, including multiple myeloma and monoclonal gammopathies of undetermined significance (MGUS), amyloidosis and rare plasma cell dyscrasias (plasma-cell leukemias, POEMS syndrome).

Editorial activity

- Reviewer for *Annals of Hematology and Neoplasma*

Spoken languages

Italian: mother tongue

English: Excellent in writing and speaking

Scientific interests

- Diagnosis, clinics and treatment of plasma-cell disorders (Multiple myeloma, plasma-cell leukemia, monoclonal gammopathies of undetermined significance, amyloidosis and POMES syndrome).
- Minimal residual disease assessment in multiple myeloma
- Biology and genetics of multiple myeloma.
- Design and conduction of clinical trials in plasma-cell disorders, including multiple myeloma and plasma-cell leukemia.
- Autologous stem cell transplantation and novel agents for multiple myeloma
- Treatment of older adults with multiple myeloma

Ongoing projects

Currently actively involved in several national and international clinical trials, mainly focusing on multiple myeloma research.

Over the past years Dr. Mina participated, as a sub-investigator in several phase Ib, II and III clinical trials in multiple myeloma, as well as in phase III trials in AL amyloidosis.

Scientific Production

Official H-Index: 11 (Oct 2019; source: Scopus – <https://www.scopus.com/>)

ORCID ID: 0000-0002-8144-541X

Scopus Author ID: 55382956600

Full-text articles

1. Bringhen, S., **Mina, R.**, Petrucci, M. T., Gaidano, G., Ballanti, S., Musto, P., ... Larocca, A. (2019). Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled

analysis of two phase i/ii studies. *Haematologica*, 104(8), 1640–1647. <https://doi.org/10.3324/haematol.2018.208272>

2. Kaufman, J. L., **Mina, R.**, Jakubowiak, A. J., Zimmerman, T. L., Wolf, J. J., Lewis, C., ... Lonial, S. (2019). Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. *Blood Cancer Journal*, 9(1). <https://doi.org/10.1038/s41408-018-0154-8>
3. **Mina, R.**, Joseph, N. S., Kaufman, J. L., Gupta, V. A., Heffner, L. T., Hofmeister, C. C., ... Lonial, S. (2019). Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. *Cancer*, 125(3), 416–423. <https://doi.org/10.1002/cncr.31718>
4. Castella, B., **Mina, R.**, & Gay, F. (2019). CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab. *Cytometry Part A*, 95(4), 416–418. <https://doi.org/10.1002/cyto.a.23752>
5. **Mina, R.**, & Lonial, S. (2019). Is there still a role for stem cell transplantation in multiple myeloma? *Cancer*, 125(15), 2534–2543. <https://doi.org/10.1002/cncr.32060>
6. Gay, F., & **Mina, R.** (2019). Redefining the treatment paradigm for multiple myeloma. *The Lancet Oncology*, 20(6), 743–744. [https://doi.org/10.1016/S1470-2045\(19\)30295-5](https://doi.org/10.1016/S1470-2045(19)30295-5)
7. Cerrato, C., Di Raimondo, F., De Paoli, L., Spada, S., Patriarca, F., Crippa, C., ... **Mina, R.**, ... Gay, F. (2018). Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. *Journal of Cancer Research and Clinical Oncology*, 144(7), 1357–1366. <https://doi.org/10.1007/s00432-018-2641-5>
8. Bringhen, S., **Mina, R.**, Cafo, A. M., Liberati, A. M., Spada, S., Belotti, A., ... Boccadoro, M. (2018). Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. *Leukemia*, 32(8), 1803–1807. <https://doi.org/10.1038/s41375-018-0024-1>
9. **Mina, R.**, Petrucci, M. T., Corradini, P., Spada, S., Patriarca, F., Cerrato, C., ... Bringhen, S. (2018). Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. *Clinical Lymphoma, Myeloma and Leukemia*, 18(8), 533–540. <https://doi.org/10.1016/j.clml.2018.05.019>
10. **Mina, R.**, D'Agostino, M., Cerrato, C., Gay, F., & Palumbo, A. (2017). Plasma cell leukemia: update on biology and therapy. *Leukemia and Lymphoma*, 58(7), 1538–1547. <https://doi.org/10.1080/10428194.2016.1250263>
11. Larocca, A., **Mina, R.**, Gay, F., Bringhen, S., & Boccadoro, M. (2017). Emerging drugs and combinations to treat multiple myeloma. *Oncotarget*, 8(36), 60656–60672. <https://doi.org/10.18632/oncotarget.19269>
12. Magarotto, V., Bringhen, S., Offidani, M., Benevolo, G., Patriarca, F., **Mina, R.**, ... Palumbo, A. (2016). Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. *Blood*, 127(9), 1102–1108. <https://doi.org/10.1182/blood-2015-08-662627>
13. **Mina, R.**, Cerrato, C., Bernardini, A., Aghemo, E., & Palumbo, A. (2016). New pharmacotherapy options for multiple myeloma. *Expert Opinion on Pharmacotherapy*, 17(2), 181–192. <https://doi.org/10.1517/14656566.2016.1115016>
14. **Mina, R.**, & Palumbo, A. (2015). *Multiple myeloma. Management of Hematological Cancer in Older People*. https://doi.org/10.1007/978-1-4471-2837-3_12
15. Ozaki, S., Harada, T., Saitoh, T., Shimazaki, C., Itagaki, M., Asaoku, H., ... **Mina, R.**, ... Shimizu, K. (2014). Survival of multiple myeloma patients aged 65–70 years in the era of novel agents and autologous stem cell transplantation. *Acta Haematologica*, 132(2), 211–219. <https://doi.org/10.1159/000357394>
16. Bringhen, S., Gay, F., Donato, F., Troia, R., **Mina, R.**, & Palumbo, A. (2014). Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma. *Expert Opinion on Investigational Drugs*, 23(9), 1193–1209. <https://doi.org/10.1517/13543784.2014.920821>
17. Musto, P., Simeon, V., Martorelli, M. C., Petrucci, M. T., Cascavilla, N., Di Raimondo, F., ... **Mina, R.**, ... Palumbo, A. (2014). Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. *Leukemia*, 28(1), 222–225. <https://doi.org/10.1038/leu.2013.241>

18. Palumbo, A., Bringhen, S., Larocca, A., Rossi, D., Di Raimondo, F., Magarotto, V., ... **Mina, R.**, ... Cavo, M. (2014). Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: Updated follow-up and improved survival. *Journal of Clinical Oncology*, 32(7), 634–640. <https://doi.org/10.1200/JCO.2013.52.0023>
19. Cerrato, C., **Mina, R.**, & Palumbo, A. (2014). Optimal management of elderly patients with myeloma. *Expert Review of Anticancer Therapy*, 14(2), 217–228. <https://doi.org/10.1586/14737140.2014.856269>
20. Palumbo, A., **Mina, R.**, Cerrato, C., & Cavallo, F. (2013). Role of consolidation/maintenance therapy in multiple myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, 13(SUPPL. 2). <https://doi.org/10.1016/j.clml.2013.05.009>
21. Palumbo, A., & **Mina, R.** (2013). Part II: Role of maintenance therapy in transplant-ineligible patients. *JNCCN Journal of the National Comprehensive Cancer Network*, 11(1), 43–49. <https://doi.org/10.6004/jnccn.2013.0007>
22. Gay, F., **Mina, R.**, Troia, R., & Bringhen, S. (2013). Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. *Expert Opinion on Drug Metabolism and Toxicology*, 9(11), 1517–1527. <https://doi.org/10.1517/17425255.2013.827169>
23. Bringhen, S., Mateos, M. V., Zweegman, S., Larocca, A., Falcone, A. P., Oriol, A., ... **Mina, R.**, ... Palumbo, A. (2013). Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials. *Haematologica*, 98(6), 980–987. <https://doi.org/10.3324/haematol.2012.075051>
24. Palumbo, A., & **Mina, R.** (2013). Management of older adults with multiple myeloma. *Blood Reviews*, 27(3), 133–142. <https://doi.org/10.1016/j.blre.2013.04.001>
25. Larocca, A., Montefusco, V., Bringhen, S., Rossi, D., Crippa, C., **Mina, R.**, ... Palumbo, A. (2013). Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: A multicenter phase 1/2 open-label study. *Blood*, 122(16), 2799–2806. <https://doi.org/10.1182/blood-2013-03-488676>
26. Falco, P., Cavallo, F., Larocca, A., Rossi, D., Guglielmelli, T., Rocci, A., ... **Mina, R.**, ... Palumbo, A. (2013). Lenalidomide-prednisone induction followed by lenalidomide-melphalan- prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. *Leukemia*, 27(3), 695–701. <https://doi.org/10.1038/leu.2012.271>
27. Larocca, A., Cavallo, F., **Mina, R.**, Boccadoro, M., & Palumbo, A. (2012). Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. *Future Oncology*, 8(10), 1223–1238. <https://doi.org/10.2217/fon.12.124>

Book chapters

1. **Roberto Mina**, Alessandra Larocca, and Antonio Palumbo. *Haemopoietic diseases: leukaemias and myelomas*. In: Michel J-P, Beattie BL, Martin FC, Walston JD (Eds). *Oxford Textbook of Geriatric Medicine*. Oxford University Press: Oxford, 2017.
2. **Roberto Mina** and Antonio Palumbo. *Multiple Myeloma*. In: Wedding U., Audisio R. (Eds). *Management of Hematological Cancer in Older People*. Springer: London, 2015.

Abstracts

1. Alessandra Larocca, Paolo Corradini, **Roberto Mina**, Nicola Cascavilla, Anna Marina Liberati , Norbert Pescosta, Maria Teresa Petrucci, Giovannino Ciccone, Andrea Capra, Francesca Patriarca, Delia Rota Scalabrini, Vanessa Innao, Marco Poggiu, Michele Cea, Renato Zambello,

Anna Baraldi, Angelo Belotti, Claudia Cellini, Monica Galli, Mariella Grasso, Sara Aquino, Gloria Margiotta Casaluci, Giovanni De Sabbata, Stelvio Ballanti, Massimo Offidani, Katia Mancuso, Mario Boccadoro, Sara Bringhen.

Efficacy and Safety of Ixazomib-dexamethasone, Ixazomib-Cyclophosphamide-dexamethasone, Ixazomib-Thalidomide-dexamethasone and Ixazomib-Bendamustine-dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized UNITO-EMN10 Study. Abstract #3195 [ASH 2019 61st Meeting].

2. **R. Mina**, A. Larocca, A. Belotti, C. Conticello, F. Monaco, M. Offidani, S. Ronconi, M. Marchetti, R. Ria, M.L. Mosca-Siez, N. Pescosta, M. Grasso, A. Capra, R. Zambello, M. Pogggiu, N. Giuliani, S. Ballanti, C. Cellini, A.M. Liberati, A. Siniscalchi, M.T. Petrucci, A. Palumbo, P. Musto, P. Sonneveld, M. Boccadoro.
Maintenance Therapy vs Re-treatment at Biochemical Relapse vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II, Randomized Study. Abstract #357 [17th International Myeloma Workshop (IMW) 2019].
3. **R. Mina**, A. Larocca, A. Belotti, C. Conticello, F. Monaco, M. Offidani, S. Ronconi, M. Marchetti, R. Ria, A. Conconi, N. Pescosta, M. Grasso, A. Capra, R. Zambello, M. Pogggiu, N. Giuliani, S. Ballanti, C. Cellini, A.M. Liberati, T. Caravita, M. T. Petrucci, A. Palumbo, P. Musto, P. Sonneveld, M. Boccadoro.
Maintenance therapy vs Re-treatment at Biochemical Relapse vs Observation in Relapsed/Refractory Multiple Myeloma (RRMM) Patients: Results of a Phase II, Randomized Study. Abstract #P035 [Italian Society of Hematology (SIE) 2019 National Congress].
4. **Roberto Mina**, Alessandra Larocca, MariaTeresa Petrucci, Gianluca Gaidano, Stelvio Ballanti, Pellegrino Musto, Massimo Offidani, Paola Omedé, Giulia Benevolo, Alessandra Malfitano, Piero Galieni, Michele Cavo, Tommaso Caravita di Toritto, Vittorio Del Fabro, Vittorio Montefusco, Antonio Palumbo, Mario Boccadoro and Sara Bringhen.
Long-Term Carfilzomib for High-Risk Patients with Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies. Blood 2018 132:3240. ASH 2018
5. Sara Bringhen, **Roberto Mina**, Maria Teresa Petrucci, Lorenzo De Paoli, Stelvio Ballanti, Pellegrino Musto, Massimo Offidani, Stefano Spada, Giulia Benevolo, Elena Ponticelli, Piero Galieni, Michele Cavo, Tommaso Caravita di Toritto, Concetta Conticello, Vittorio Montefusco, Antonio Palumbo, Mario Boccadoro and Alessandra Larocca.
Once Weekly Versus Twice Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies. Blood 2018 132:1990
6. **Roberto Mina**, Nisha Joseph, Francesca Gay, Ajay Nooka, Efstathios Kastitis, Stefano Spada, Maria Teresa Petrucci, Jonathan L. Kaufman, Vittorio Montefusco, Maria Gavriatopoulous, Francesca Patriarca, Milena Gilestro, Lawrence H. Boise, Concetta Conticello, Sonia Grandi, Maria Roussou, Nicola Giuliani, Anna Marina Liberati, Dhvani Almaula, Massimo Offidani, Rossella Ribolla, David L. Jaye, Lorenzo De Paoli, Evangelos Terpos, Sagar Lonial, Mario Boccadoro, Meletios A. Dimopoulos.
Translocation (14;16) Positive Multiple Myeloma Patients: Clinical Features And Survival Outcomes Of A High-Risk Population. Jun 15, 2018; 215039. EHA 2018
7. **Roberto Mina**, Alessandra Larocca, Angelo Belotti, Francesco Di Raimondo, Anna Baraldi, Massimo Offidani, Monia Marchetti, Roberto Ria, Annarita Conconi, Norbert Pescosta, Mariella Grasso, Giusy Cetani, Anna Maria Cafro, Roberto Passera, Rossella Troia, Gianpietro Semenzato, Nicola Giuliani, Stelvio Ballanti, Claudia Cellini, Anna Marina Liberati, Tommaso

Caravita di Toritto, Maria Teresa Petrucci, Pellegrino Musto, Antonio Palumbo, Pieter Sonneveld and Mario Boccadoro.

Bortezomib-Dexamethasone Re-Treatment at Biochemical Relapse Vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II Multi-Center, Randomized Study. Blood 2017 130:3128; ASH 2017

8. Sara Bringhen, **Roberto Mina**, Maria Teresa Petrucci, Nicola Giuliani, Emanuele Angelucci, Mariella Genuardi, Tommaso Caravita di Toritto, Alessandra Malfitano, Pellegrino Musto, Roberto Ria, Giovannino Ciccone, Elona Saraci, Massimo Offidani, Caterina Musolino, Rossella Troia, Anna Marina Liberati, Lorenzo De Paoli, Stelvio Ballanti, Fabrizio Esma, Piero Galieni, Michele Cavo, Concetta Conticello, Renato Zambello, Paolo Corradini, Giulia Benevolo, Antonio Palumbo, Pieter Sonneveld, Mario Boccadoro
Incidence and risk factors of cardiovascular adverse events in a large population of newly-diagnosed, transplant ineligible myeloma patients treated with carfilzomib. May 18, 2017; 181023. EHA 2017
9. **Roberto Mina**, Maria Teresa Petrucci, Nicola Giuliani, Angelo Michele Carella, Mariella Genuardi, Tommaso Caravita di Toritto, Elena Ponticelli, Pellegrino Musto, Roberto Ria, Giovannino Ciccone, Elona Saraci, Massimo Offidani, Caterina Musolino, Rossella Troia, Anna Marina Liberati, Lorenzo De Paoli, Stelvio Ballanti, Fabrizio Esma, Piero Galieni, Michele Cavo, Concetta Conticello, Renato Zambello, Paolo Corradini, Patrizia Pregno, Antonio Palumbo, Pieter Sonneveld, Mario Boccadoro, Sara Bringhen
Cardio-vascular toxicity in newly diagnosed, transplant-ineligible multiple myeloma patients treated with Carfilzomib, cyclophosphamide and dexamethasone: results from an integrated analysis of 3 phase I/II trials. Abstract e10 | 16th International Myeloma Workshop, March 1-4, 2017
10. Valeria Magarotto, Sara Bringhen, Massimo Offidani, Giulia Benevolo, Francesca Patriarca, **Roberto Mina**, Antonietta Pia Falcone, Lorenzo De Paoli, Giuseppe Pietrantuono, Silvia Gentili, Caterina Musolino, Nicola Giuliani, Annalisa Bernardini, Concetta Conticello, Stefano Pulini, Giovannino Ciccone, Vladimír Maisnar, Marina Ruggeri, Renato Zambello, Tommasina Guglielmelli, Antonio Ledda, Anna Marina Liberati, Vittorio Montefusco, Roman Hajek, Mario Boccadoro and Antonio Palumbo.
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood 2016 127:1102-1108. ASH 2016
11. Chiara Cerrato, Francesca Gay, Maria Teresa Petrucci, Pellegrino Musto, Gianluca Gaidano, Massimo Offidani, Tommasina Guglielmelli, Marco Salvini, Francesca Patriarca, Elena Ponticelli, Gianpietro Semenzato, Francesco Di Raimondo, **Roberto Mina**, Nicola Cascavilla, Dina Ben Yehuda, Daniela Oddolo, Paolo Corradini, Lucio Catalano, Paolo Di Bartolomeo, Roman Hájek, Andrew Spencer, Mario Boccadoro and Antonio Palumbo.
Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. Blood 2015 126:1974; ASH 2015
12. **Roberto Mina**, Alessandra Larocca, Massimo Offidani, Sara Bringhen, Tommaso Caravita, Valeria Magarotto, Lucia Pantani, Francesco Di Raimondo, Alberto Bosi, Iolanda D. Vincelli, Paola Tacchetti, Gianluca Gaidano, Sonia Grandi, Caterina Musolino, Chiara Cerrato, Ludek Pour, Monica Astolfi, Giuseppe Rossi, Fausto Rossini, Maria T. Petrucci, Roberto Ria, Annalisa Pezzi, Roman Hajek, Michele Cavo, Andrew Spencer, Mario Boccadoro and Antonio Palumbo.

Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. Blood 2015 126:927; ASH 2015

13. S. Bringhen, D. Rossi, P. Sonneveld, A. Larocca, F. Gentilini, P. Galieni, A. Malfitano, R. Passera, M. Offidani, A.M. Liberati, **R. Mina**, G. Gaidano, M. Boccadoro, P. Corradini, A. Palumbo.
Phase 1-2 clinical study of weekly carfilzomib in combination with cyclophosphamide and dexamethasone at diagnosis. Haematologica. EHA 2015
14. **R. Mina**, A. Larocca, M. Offidani, V. Magarotto, T. Caravita, R. van der Holt, F. Di Raimondo, A. Bosi, I.D. Vincelli, S. Croockewit, G. Gaidano, S. Grandi, C. Musolino, C. Cerrato, P. Lud k, M. Ruggeri, G. Rossi, F. Rossini, M.T. Petrucci, R. Ria, S. Zweegman, R. Hajek, A. Spencer, M. Boccadoro, P. Sonneveld, A. Palumbo.
Impact of complete response on progression-free survival and overall survival in newly diagnosed myeloma patients treated with autologous stem cell transplantation or conventional chemotherapy: results of a pooled analysis of 5 phase III trials. Clinical lymphoma myeloma and leukemia. IMW2015
15. Alessandra Larocca, Sara Bringhen, Roman Hajek, Maria Teresa Petrucci, Massimo Offidani, **Roberto Mina**, Vittorio Montefusco, Gabriele Aitoro, Claudia Cellini, Enrico Maria Pogliani, Lorenzo De Paoli, Marina Ruggeri, Laura Maracci, Oreste Villani, Chiara Nozzoli, Alessia La Fauci, Marta Chisini, Francesca Gay, Roberto Marasca, Stelvio Ballanti, Nicola Giuliani, Pellegrino Musto, Mario Boccadoro, Pieter Sonneveld and Antonio Palumbo.
The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy. Blood 2014 124:4740; ASH 2014
16. Alessandra Larocca, Vittorio Montefusco, Sara Bringhen, Davide Rossi, Claudia Crippa, **Roberto Mina**, Monica Galli, Magda Marcatti, Giacinto La Verde, Nicola Giuliani, Valeria Magarotto, Tommasina Guglielmelli, Delia Rota-Scalabrini, Paola Omedé, Alberto Santagostino, Ileana Baldi, Angelo Michele Carella, Mario Boccadoro, Paolo Corradini and Antonio Palumbo.
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood 2013 122:2799-2806. ASH 2013
17. Alessandra Larocca, Federica Cavallo, Valeria Magarotto, Massimo Offidani, Vincenzo Federico, Vanessa Innao, Antonietta Pia Falcone, Alessandra Romano, Tommaso Caravita, Davide Rossi, Giovanna Mansueto, **Roberto Mina**, Chiara Nozzoli, Giulia Benevolo, Tommasina Guglielmelli, Anna Marina Liberati, Daniele Derudas, Stefania Oliva, Fortunato Morabito, Angelo Michele Carella, Silvia Gentili, Elona Saraci, Maria Teresa Petrucci, Pieter Sonneveld, Mario Boccadoro and Antonio Palumbo.
Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age. Blood 2013 122:539; ASH 2013
18. Antonio Palumbo, Alessandra Larocca, Vittorio Montefusco, Davide Rossi, Angelo Michele Carella, **Roberto Mina**, Claudia Crippa, Mariella Sciacca, Monica Galli, Delia Rota Scalabrini, Magda Marcatti, Tommasina Guglielmelli, Nicola Giuliani, Giacinto La Verde, Ileana Baldi, Vittorio Emanuele Muccio, Mario Boccadoro and Paolo Corradini.
Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma. Blood 2012 120:446; ASH 2012

I authorize the processing of my personal data pursuant to art. 13 of Legislative Decree 30 June 2003, n. 196 "Code regarding the protection of personal data" and art. 13 of the GDPR (EU Regulation 2016/679).

Torino, October 22nd, 2018

Dr. Roberto Mina